Analgesic effect of neuromodulation using the AT-04 portable magnetic field-generating device in a patient with neuropathic pain: a case report.

Pub Date : 2024-02-10 DOI:10.1186/s40981-024-00694-4

Atsushi Sawada, Michiaki Yamakage

{"title":"Analgesic effect of neuromodulation using the AT-04 portable magnetic field-generating device in a patient with neuropathic pain: a case report.","authors":"Atsushi Sawada, Michiaki Yamakage","doi":"10.1186/s40981-024-00694-4","DOIUrl":null,"url":null,"abstract":"Background: Neuromodulation by magnetic field through the AT-04 (ait® (AT-04); Peace of Mind Co., Ltd., Kumamoto, Japan) has improved allodynia in neuropathic pain model rats. This report focuses on neuromodulation through magnetic field exposure using the AT-04 that provided an analgesic effect in a patient with neuropathic pain.Case presentation: A 47-year-old man presented with flaccid paralysis and extensive neuropathic pain and scored 7 on the 11-point Numerical Rating Scale (NRS) for his left upper limb. The patient was treated with neuromodulation by magnetic field exposure using the AT-04. Baseline NRS scores were obtained three times daily during the baseline period (days 1-5). Magnetic field exposure was then performed for 30 min three times daily (morning, noon, and evening) at home for 36 days, which was termed the intervention period (days 6-41). During the baseline period, the median NRS score was 7 and the baseline NRS score for calculating the percentage of nonoverlap data (PND) was 6. During the intervention period, the median NRS score was 4 and the PND value of the NRS score was 77.8% (28/36). Neuromodulation by magnetic field exposure using the AT-04 effectively decreased the patient's NRS score. The patient had no adverse effects during the intervention period.Conclusions: Neuromodulation by magnetic field exposure using the AT-04 was effective in decreasing the NRS score in a patient with neuropathic pain. The AT-04 portable magnetic field-generating device shows potential as a therapeutic option for refractory neuropathic pain.","PeriodicalId":0,"journal":{"name":"","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10857986/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40981-024-00694-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Neuromodulation by magnetic field through the AT-04 (ait® (AT-04); Peace of Mind Co., Ltd., Kumamoto, Japan) has improved allodynia in neuropathic pain model rats. This report focuses on neuromodulation through magnetic field exposure using the AT-04 that provided an analgesic effect in a patient with neuropathic pain.

Case presentation: A 47-year-old man presented with flaccid paralysis and extensive neuropathic pain and scored 7 on the 11-point Numerical Rating Scale (NRS) for his left upper limb. The patient was treated with neuromodulation by magnetic field exposure using the AT-04. Baseline NRS scores were obtained three times daily during the baseline period (days 1-5). Magnetic field exposure was then performed for 30 min three times daily (morning, noon, and evening) at home for 36 days, which was termed the intervention period (days 6-41). During the baseline period, the median NRS score was 7 and the baseline NRS score for calculating the percentage of nonoverlap data (PND) was 6. During the intervention period, the median NRS score was 4 and the PND value of the NRS score was 77.8% (28/36). Neuromodulation by magnetic field exposure using the AT-04 effectively decreased the patient's NRS score. The patient had no adverse effects during the intervention period.

Conclusions: Neuromodulation by magnetic field exposure using the AT-04 was effective in decreasing the NRS score in a patient with neuropathic pain. The AT-04 portable magnetic field-generating device shows potential as a therapeutic option for refractory neuropathic pain.

查看原文

使用 AT-04 便携式磁场发生装置对神经病理性疼痛患者进行神经调控的镇痛效果：病例报告。

背景：通过 AT-04（ait® (AT-04)；Peace of Mind Co., Ltd., Kumamoto, Japan）进行磁场神经调控改善了神经病理性疼痛模型大鼠的异动症。本报告的重点是使用 AT-04 通过磁场照射进行神经调节，从而为一名神经病理性疼痛患者提供镇痛效果：一名 47 岁的男子出现弛缓性瘫痪和广泛的神经病理性疼痛，左上肢在 11 点数字评定量表（NRS）中得分为 7 分。患者接受了使用 AT-04 进行磁场照射的神经调控治疗。在基线期（第 1-5 天），每天三次获得基线 NRS 分数。然后在家中进行磁场照射，每天三次，每次 30 分钟（早、中、晚），持续 36 天，称为干预期（第 6-41 天）。在基线期，NRS 评分的中位数为 7 分，用于计算无重叠数据百分比（PND）的基线 NRS 评分为 6 分；在干预期，NRS 评分的中位数为 4 分，NRS 评分的 PND 值为 77.8%（28/36）。使用 AT-04 通过磁场照射进行神经调控，有效降低了患者的 NRS 评分。患者在干预期间未出现任何不良反应：结论：使用 AT-04 通过磁场照射进行神经调控能有效降低神经病理性疼痛患者的 NRS 评分。AT-04便携式磁场发生装置具有治疗难治性神经病理性疼痛的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文